XML 84 R26.htm IDEA: XBRL DOCUMENT v2.4.0.6
Concentrations
3 Months Ended
Mar. 31, 2012
Concentrations  
Concentrations

(19) Concentrations

(a)    Limited Number of Products

Molycorp Mountain Pass

        Percentages of Molycorp Mountain Pass' revenue, net of intercompany sales, by product that accounted for more than 10% of consolidated sales in the first quarter of 2012 or 2011, were approximately as follows:

 
  March 31,
2012
  March 31,
2011
 

Lanthanum products

    46 %   44 %

Cerium products

    1 %   34 %

Didymium, Neodymium and Praseodymium products

    53 %   18 %

Molycorp Silmet

        The majority of sales from the Molycorp Silmet facility during the first quarter of 2012, net of intercompany sales, consisted of cerium, neodymium and praseodymium rare earth products, and two rare metal products, tantalum and niobium.

MMA

        The MMA facility sold primarily NdFeB alloys and samarium-cobalt alloys during the first quarter of 2012. MMA's sales of NdFeB alloys for the same period were approximately 19% of consolidated sales.

(b)    Limited Number of Customers

Molycorp Mountain Pass

        In the first quarter of 2012, Molycorp Mountain Pass' sales to two of its customers in excess of 10% of consolidated sales were $20.4 million and $17.2 million, respectively. Molycorp Mountain Pass' sales to three of its customers, net of intercompany sales, represented in total approximately 98% of Molycorp Mountain Pass' sales in same period.

        For the three months ended March 31, 2011, approximately 75% of Molycorp Mountain Pass' total sales were to three of its customers. Sales to these three customers were approximately $7.8 million, $6.2 million and $5.8 million, respectively.

Molycorp Silmet

        Sales to four of Molycorp Silmet's customers during the first quarter of 2012 represented, in aggregate, approximately 57% of Molycorp Silmet's sales for that period.

MMA

        MMA's sales to one of its customers for the three months ended March 31, 2012, were $16.6 million, or approximately 20% of the Company's consolidated sales, and approximately 88% of MMA's sales for that period.